Novo Nordisk has launched its Wegovy weight-loss pill in the United States at lower prices. The once-daily pill is the first GLP-1 weight-loss tablet available on the market. It costs significantly less than injectable versions, accelerating competition across the sector. The drug received US approval shortly before Christmas and is now widely available. Cash-paying patients can buy the starting dose for $149 per month. Injectable GLP-1 drugs typically cost around $1,000 monthly. Novo hopes the pill will expand access for millions living with obesity. The launch pressures rivals such as Eli Lilly, which is developing its own obesity pill. Wegovy tablets are available through major pharmacies including CVS and Costco. Novo’s shares rose after the announcement despite intense competition.
Novo Nordisk Launches Wegovy Weight-Loss Pill in US, Intensifying Price War
Andrew Rogers
Andrew Rogers is a freelance journalist based in Chicago, USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He graduated with a degree in Journalism from the University of Florida. Over the years, he has contributed to leading outlets such as The New York Times, CNN, and Reuters. Recognized for his sharp reporting and thoughtful analysis, Andrew delivers accurate and timely news that keeps readers updated on key national and global developments.
Add A Comment
